Kymera Therapeutics (KYMR) EBIT Margin (2019 - 2025)
Historic EBIT Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 3347.36%.
- Kymera Therapeutics' EBIT Margin fell 14194300.0% to 3347.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 139604.62%, marking a year-over-year increase of 1398332500.0%. This contributed to the annual value of 8439.84% for FY2024, which is 82292200.0% down from last year.
- Kymera Therapeutics' EBIT Margin amounted to 3347.36% in Q3 2025, which was down 14194300.0% from 736.82% recorded in Q2 2025.
- Over the past 5 years, Kymera Therapeutics' EBIT Margin peaked at 220.77% during Q4 2024, and registered a low of 3347.36% during Q3 2025.
- Over the past 5 years, Kymera Therapeutics' median EBIT Margin value was 336.77% (recorded in 2025), while the average stood at 573.79%.
- As far as peak fluctuations go, Kymera Therapeutics' EBIT Margin soared by 2980900bps in 2021, and later plummeted by -14194300bps in 2025.
- Kymera Therapeutics' EBIT Margin (Quarter) stood at 222.55% in 2021, then dropped by -8bps to 239.36% in 2022, then soared by 83bps to 40.33% in 2023, then soared by 647bps to 220.77% in 2024, then tumbled by -1616bps to 3347.36% in 2025.
- Its EBIT Margin was 3347.36% in Q3 2025, compared to 736.82% in Q2 2025 and 336.77% in Q1 2025.